Literature DB >> 16538171

Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis.

Chunping Li1, Wei Wu, Jia Liu, Lixin Qian, Aiping Li, Kehu Yang, Qingyi Wei, Jianwei Zhou, Zhengdong Zhang.   

Abstract

BACKGROUND: FAS and FASLG together initiate apoptosis, which prevents tumor development. FAS and FASLG polymorphisms in the promoter regions can alter the transcriptional activities and thus alter risk of cancer. We hypothesized that the FAS -1377G>A, -670A>G, and FASLG -844T>C polymorphisms are associated with risk of bladder cancer.
METHODS: In a hospital-based case-control study of 216 case patients with newly diagnosed bladder transitional cell carcinoma and 252 cancer-free controls frequency-matched by age and sex, we genotyped polymorphisms using PCR-restriction fragment length polymorphism.
RESULTS: We found a statistically significantly increased risk of bladder cancer associated with the FASLG -844CC genotype [adjusted OR=1.51; 95% CI 1.03-2.23] compared with -844 (CT+TT). Consistently, the FAS haplotype genotypes with 2-4 variant (risk) alleles (-1377A and -670A) were associated with an increased risk of bladder cancer compared to 0-1 variants (OR=2.14; 95% CI 1.10-4.16). Furthermore, when we evaluated these three polymorphisms together, we found that the combined genotypes with 4-6 variant (risk) alleles (-1377A, -670A, and -844C) were associated with an increased risk of bladder cancer (OR=1.58; 95% CI 1.07-2.34) compared to 1-3 variants, and this increased risk was more pronounced among subgroups of aged >50 years (OR=1.70; 95% CI 1.11-2.61) and smokers (OR=1.88; 95% CI 1.06-3.32).
CONCLUSIONS: FAS and FASLG polymorphisms appear to jointly contribute to risk of bladder cancer in this southern Chinese population. Larger studies are needed to verify these findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16538171     DOI: 10.1097/01.fpc.0000194425.58511.a7

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  17 in total

1.  FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls.

Authors:  Li-Xin Qiu; Jian Shi; Hui Yuan; Xin Jiang; Kai Xue; Hai-Feng Pan; Jin Li; Ming-Hua Zheng
Journal:  Hum Genet       Date:  2009-02-19       Impact factor: 4.132

2.  Apoptosis-related Fas and FasL gene polymorphisms' associations with knee osteoarthritis.

Authors:  Melek Sezgin; İbrahim Ömer Barlas; Seyfi Yıldır; Gözde Türköz; Handan Çamdeviren Ankaralı; Günşah Şahin; Mehmet Emin Erdal
Journal:  Rheumatol Int       Date:  2013-02-08       Impact factor: 2.631

3.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

4.  Polymorphisms of methylenetetrahydrofolate reductase and methionine synthase genes and bladder cancer risk: a case-control study with meta-analysis.

Authors:  Meilin Wang; Haixia Zhu; Guangbo Fu; Miaomiao Wang; Zhizhong Zhang; Qiang Lu; Shizhi Wang; Zhengdong Zhang
Journal:  Clin Exp Med       Date:  2008-09-25       Impact factor: 3.984

5.  Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer.

Authors:  Cavit Ceylan; Sedat Yahşi; Serkan Doğan; Elife ÖztÜrk; Gulay Ceylan
Journal:  Ir J Med Sci       Date:  2018-02-16       Impact factor: 1.568

6.  Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.

Authors:  Monica Ter-Minassian; Rihong Zhai; Kofi Asomaning; Li Su; Wei Zhou; Geoffrey Liu; Rebecca Suk Heist; Thomas J Lynch; John C Wain; Xihong Lin; Immaculata De Vivo; David C Christiani
Journal:  Carcinogenesis       Date:  2008-08-29       Impact factor: 4.944

7.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

8.  CD95 rs1800682A/G variant and tumor risk in Asians: evidence from a meta-analysis of 36 case-control studies containing 22,438 samples.

Authors:  Cheng Jin; Xiaomin Wu; Yuanlong Gu; Fenglai Yuan; Qinghai Ye; Feng Dai; Lijie Zhu; Yuanyuan Mi
Journal:  Med Sci Monit       Date:  2015-02-27

9.  FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.

Authors:  Hongguang Zhao; Wenhu Chen; Peng Du; Aihua Sun; Chenyu Zhuang; Jiali Tong; Lifang Wang
Journal:  Tumour Biol       Date:  2015-01-18

10.  A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival.

Authors:  Guenter Hofmann; Uwe Langsenlehner; Tanja Langsenlehner; Babak Yazdani-Biuki; Heimo Clar; Armin Gerger; Florentine Fuerst; Hellmut Samonigg; Peter Krippl; Wilfried Renner
Journal:  J Cell Mol Med       Date:  2009-02-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.